Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.
Sarah E HoldenChristopher Ll MorganQing QiaoSara Jenkins-JonesEllen R BerniCraig J CurriePublished in: Diabetes, obesity & metabolism (2017)
Overall, exenatide once-weekly and twice-daily-based regimens were associated with reduced healthcare resource use and costs compared with basal-insulin-based regimens.